A, Expression levels of OXPHOS complex subunits and FAK in LNCaP and E006AA cells by immunoblot analysis. NDUFA9 for Complex I, succinate dehydrogenase A (SDHA) for Complex II, UQCRC2 for Complex III, cytochrome c oxidase subunit IV (COX IV) for Complex IV; ATP5A for Complex V. GAPDH serves as a loading control. B, Expression level of glycolytic enzymes including focal adhesion kinase (FAK), hexokinase 1 (HK1), hexokinase 2 (HK2), phosphofructokinase platelet isoform (PFKP), pyruvate kinase M ½ (PKM ½), and lactate dehydrogenase A (LDHA) in LNCaP and E006AA cells using immunoblot analysis. GAPDH serves as a loading control. C, Expression of LDHA at mRNA level using RT-PCR in LNCaP and E006AA cells. D, Expression of LDHA at mRNA level using RT-PCR in primary tumor isolated from AA and CA men with PCa. E, Measurement of glycolytic reserve capacity in PC-3, DU145, and E006AA cells using Seahorse XF analyzer. F, Cell death quantification in E006AA cells treated with DOC alone or DOC in combination with glycolytic disruptor 3-BrPA (3-Bromopyruvate) for 24 hrs. G, Measurement of glycolytic reserve capacity using Seahorse XF analyzer in E006AA cells treated with DOC or DOC in combination with either c-Myc inhibitor or NF-κB inhibitor or AKT activator. H, Measurement of mitochondrial ROS production using MitoSOX dye in E006AA cells treated with DOC or DOC in combination with either c-Myc inhibitor or NF-κB inhibitor or AKT activator using flow cytometry. I, Expression level of glycolytic enzymes including hexokinase 1 (HK1), hexokinase 2 (HK2), phosphofructokinase platelet isoform (PFKP), pyruvate kinase M 2 (PKM2), and lactate dehydrogenase A (LDHA) in mock- and CC- silenced LNCaP cells using immunoblot analysis. Actin serves as a loading control. Data represent mean ± SD of 3 independent experiments. Significant differences between means were assessed using analysis of variance (ANOVA) and GraphPad Prism Version 6.0. *p < 0.05 vs respective controls.